GRAFT VS HOST DISEASE

This early-phase study tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving a half-matched stem cell transplant for blood cancers. About 41 participants will take the drugs before and af…

This study tests a device that removes certain immune cells from donated stem cells before transplant. The goal is to lower the risk of graft-versus-host disease, a serious complication where donor cells attack the patient's body. Up to 90 children and young adults (ages 0-30) wi…

This early-phase study tests a new way to do stem cell transplants for people with aggressive or returning acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially processed donor cells to reduce the risk of graft-versus-host disease, aiming to…

This study tests whether giving more doses of the drug abatacept after a stem cell transplant can better prevent severe graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. About 160 people aged 2 and older receiving a partially ma…

This study tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help people with severe gut graft-versus-host disease that hasn't responded to steroids. About 35 adults who had a stem cell transplant and now have this complication will receive t…

This study tests a daily pill called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't improved after at least two prior treatments. cGVHD is an immune system problem that can happen after a stem cell transplant, causing damage to…

This study tests whether adding the drug belumosudil to standard care can better prevent graft-versus-host disease (GVHD) in adults with blood cancer who have had a stem cell transplant. About 46 participants will receive belumosudil alongside their usual GVHD prevention medicine…

This study tests whether adding etanercept to the standard drug ruxolitinib works better for severe graft-versus-host disease (GVHD) that doesn't respond to steroids. GVHD is a life-threatening complication after a stem cell transplant where donor cells attack the patient's body.…

This study tests the drug ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGVHD) that did not improve with steroids. cGVHD is a complication after a stem cell transplant where the donor cells attack the patient's body. The main goal i…

This study tests a personalized approach to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. Instead of giving the anti-CMV drug letermovir for a fixed 100 days, researchers will use a blood test to check when each patient's immune syste…

This study looks at whether a home-based exercise program (aerobic and resistance training) is practical and helpful for adults who develop graft-versus-host disease after a stem cell transplant and are starting high-dose steroids. About 36 participants will either do the exercis…

This study provides long-term follow-up care for people who received a donor stem cell transplant at the NIH. Participants are monitored yearly for late effects, disease relapse, and overall health. The goal is to improve care and understand long-term outcomes for transplant surv…

This study looks at why some people who have had a stem cell transplant continue to feel extremely tired and have trouble thinking clearly. Researchers will use brain scans and spinal fluid tests to see if inflammation in the brain is the cause. The goal is to better understand t…

This study is developing a symptom questionnaire specifically for children and teens (ages 5-17) who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Current symptom scales are designed for adults, but children may describe their symptoms differently. …

This study looks at how the collection of bacteria, fungi, and viruses in the vagina changes in women who receive a stem cell transplant. Researchers want to learn why some women develop a painful condition called vulvovaginal graft-versus-host disease (GVHD). About 40 women will…